^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + IO102-IO103 (PD-L1 inhibitor, IDO inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-term follow-up and subgroup analyses of metastatic melanoma patients treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Published date:
04/20/2023
Excerpt:
A subgroup analysis revealed that patients with unfavorable baseline characteristics, including M1c, elevated LDH levels, and negative PD-L1, obtained favorable and durable responses….These follow-up data confirmed long-lasting activity for anti-PD-1 therapy naïve patients with metastatic melanoma treated with the IDO/PD-L1 vaccine and nivolumab with unprecedented CRR and ORR rates of 50% and 80% respectively. Importantly, patient subgroups with unfavorable prognostic baseline characteristics obtained remarkable response rates as well.
Trial ID:
